

CITATION REPORT

List of articles citing

Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

DOI: 10.1007/s40273-016-0472-2
Pharmacoeconomics, 2016, 35, 537.

Source: <https://exaly.com/paper-pdf/64694054/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
4	Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date. <i>International Journal of Clinical Practice</i> , 2016 , 70, 886-897	2.9	14
3	Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2016 , 35, 537	4.4	4
2	Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2017 , 35, 537-547	4.4	15
1	Achievement of European Society of Cardiology/European Atherosclerosis Society lipid targets in very high-risk patients: Influence of depression and sex.. <i>PLoS ONE</i> , 2022 , 17, e0264529	3.7	